Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey

Garber AM, Sculpher MJ. Cost effectiveness and payment policy. In: Pauly MV, McGuire TG, Barros PP, editors. Handbook of health economics, vol. 2. Amsterdam: Elsevier North Holland; 2011.

Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G. Methods for the economic evaluation of health care programs. 3rd ed. Oxford: Oxford University Press; 2005.

Nord E. Cost value analysis in health care: making sense out of QALYs. Cambridge: Cambridge University Press; 1999.

Dolan P, Shaw R, Tsuchiya A, Williams A. QALY maximisation and people’s preferences: a methodological review of the literature. Health Econ. 2005;14(2):197–208.

Stafinski T, Menon D, Marshall D, Caulfield T. Societal values in the allocation of healthcare resources: is it all about the health gain? Patient. 2011;4(4):207–25.

Whitty JA, Lancsar E, Rixon K, Golenko X, Ratcliffe J. A systematic review of stated preference studies reporting public preferences for healthcare priority setting. Patient. 2014;7:365–86.

Gu Y, Lancsar E, Ghijben P, Butler J, Donaldson C. Attributes and weights in health care priority setting: a systematic review of what counts and to what extent. Soc Sci Med. 2015;146:41–52.

Schlander M, Adarkwah CC, Gandjour A. budget impact of drugs for ultra-rare non-oncological diseases projected to remain moderate in Europe, discussion paper 30. Wiesbaden: Institute for Innovation and Valuation in Health Care; 2014.

Simoens S, Cassiman D, Dooms M, Picavet E. Orphan drugs for rare diseases: Is it time to revisit their special market access status? Drugs. 2012;72(11):1437–43.

Drummond M, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posted by orphan drugs. Int J Technol Assess. 2007;23(1):36–42.

Drummond M, Towse A. Orphan drugs policies: a suitable case for treatrment. Eur J Health Econ. 2014;15:335–40.

Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the orphan drug system: Break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7(74). doi: 10.1186/750-72-7-74 .

McCabe C. Is it time to revisit orphan drug policies? BMJ. 2010;341(c4777). doi: 10.1136/bmj.c4777 .

Schlander M, Garattini S, Holm S, Kolominsky-Rabas P, Nord E, Persson U, et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res. 2014;3(4):399–422.

Desser AS. Prioritizing treatment of rare diseases: a survey of preferences of Norwegian doctors. Soc Sci Med. 2013;94:56–62.

Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40–67. BMJ. 2010;341(C4715):1–6.

Mentzakis E, Stefanowska P, Hurley J. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. Health Econ Policy Law. 2011;6:405–33.

van de Wetering EJ, van Exel A, Rose JM, Hoefman RJ, Brouwer WB. Are some QALYs more equal than others? Eur J Health Econ. 2016;17(2):117–27.

McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ. 2005;331:1016.

Hughes D, Tunnage B, Yeo S. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM Int J Med. 2005;98:829–36.

Moberly T. Rationing and access to orphan drugs. Pharm J. 2005;275:569–70.

Lynley WG, Hughes DA. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ. 2013;22(8):948–64.

Dragojlovic N, Rizzardo S, Bansback N, Mitton C, Marra CA, Lynd LD. Challenges in measuring the societal values of orphan drugs: Insights from a Canadian stated preference. Patient. 2015;8(1):93–101.

Desser AS, Olsen JA, Sverre G. Eliciting preferences for prioritizing treatment of rare diseases: the role of opportunity costs and framing effects. Pharmacoeconomics. 2013;31(11):1051–61.

Nord E, Richardson J, Kuhse H, Singer P. Who cares about cost?: does economic analysis impose or reflect social values? Health Policy. 1995;34(2):79–94.

Abellan-Perpinan J-M, Pinto-Prades J-L. Health state after treatment: a reason for discrimination? Health Econ. 1999;8:701–7.

Ubel P, Loewenstein G. Distributing scarce livers: the moral reasoning of the general public. Soc Sci Med. 1996;42(7):1049–55.

Ratcliffe J. Public preferences for the allocation of donor liver grafts for transplantation. Health Econ. 2000;9:137–48.

McKie J, Shrimpton B, Richardson J, Hurworth R. The monetary value of a life year: evidence from a qualitative study of treatment costs. Health Econ. 2011;20(8):945–57.

Richardson J, Sinha K, Iezzi A, Maxwell A. Maximising health versus sharing: measuring preferences for the allocation of the health budget. Soc Sci Med. 2012;75(8):1351–61.

Richardson J, Iezzi A, Maxwell A. Why health insurance should reimburse some cost ineffective services: results from a pilot survey, Research Paper 91. Melbourne: Centre for Health Economics, Monash University; 2015.

Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371:2019–41.

Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010–2020. Orphanet J Rare Dis. 2011;27(62). doi: 10.1186/750-72-6-62 .

Alkire S, Santos M. A multidimensional approach: poverty measurement and beyond. Soc Indic Res. 2013;112:239–57.

Clark DA, Qizilbash M. Core poverty. Vagueness and adaptation: a new methodology and some results for South Africa. J Dev Stud. 2008;44:519–44.

Mitchell PM, Roberts TE, Barton PM, Coast J. Assessing sufficient capability: a new approach to economic evaluation. Soc Sci Med. 2015;139:71–9.

Rawls J. A theory of justice. Cambridge: Harvard University Press; 1971.

ABS. Estimated Resident Population (ERP) by Region, Age & Sex 2001–2013. Austalian Bureau of Statistics http://www.abs.gov.au/AUSSTATS/[email protected]/DetailsPage/3101.0Mar%202015?Open . Accessed 23 July 2015.